|
Flotetuzumab
|
伏妥珠單抗
|
1664355-28-5
|
|
OTX 008
|
|
286936-40-1
|
|
1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione
|
|
1380532-27-3
|
|
YM150
|
|
365462-23-3
|
|
SBI-425
|
|
1451272-71-1
|
|
MRTX1719
|
|
2630904-45-7
|
|
Sigma-1 receptor antagonist 2
|
|
1639220-15-7
|
|
Erucin
|
三芥子酸甘油酯
|
4430-36-8
|
|
Boc-Val-Ala-PAB-PNP
|
|
1884578-00-0
|
|
Tamtuvetmab
|
坦妥維單抗
|
1608122-71-9
|
|
Blontuvetmab
|
布隆妥維單抗
|
1608112-78-2
|
|
Tilavonemab
|
替拉奈單抗
|
2096513-89-0
|
|
Olendalizumab
|
奧侖達利珠單抗
|
1337966-73-0
|
|
Garetosmab
|
加托索單抗
|
2097125-54-5
|
|
Maftivimab
|
瑪替韋單抗
|
2135632-36-7
|
|
Andecaliximab
|
安德利昔單抗
|
1518996-49-0
|
|
Lacutamab
|
拉可妥單抗
|
2187368-16-5
|
|
Zunsemetinib
|
|
1640282-42-3
|
|
ML339
|
|
2579689-83-9
|
|
Mc-Val-Ala-PAB-PNP
|
|
1639939-40-4
|
|
YTX-465
|
|
2225824-53-1
|
|
Varisacumab
|
伐利蘇單抗
|
1610010-60-0
|
|
Istiratumab
|
艾司妥單抗
|
1509928-04-4
|
|
Bermekimab
|
貝邁奇單抗
|
1401965-15-8
|
|
Pepinemab
|
派比奈單抗
|
2097151-87-4
|
|
Ravulizumab
|
雷夫利珠單抗
|
1803171-55-2
|
|
Satralizumab
|
薩特利珠單抗
|
1535963-91-7
|
|
Cabiralizumab
|
卡比利珠單抗
|
1613144-80-1
|
|
Xentuzumab
|
珍妥珠單抗
|
1417158-65-6
|
|
Refanezumab
|
瑞法奈珠單抗
|
1233953-61-1
|
|
Bocidelpar
|
|
2095128-20-2
|
|
Tisotumab
|
替索妥單抗
|
1418628-81-5
|
|
Brazikumab
|
布雷庫單抗
|
1610353-18-8
|
|
Emapalumab
|
依瑪魯單抗
|
1709815-23-5
|
|
Camrelizumab
|
坎利珠單抗
|
1798286-48-2
|
|
Ranevetmab
|
雷奈維單抗
|
1632282-27-9
|
|
Vunakizumab
|
伏那吉珠單抗
|
1792181-33-9
|
|
Lupartumab
|
魯帕妥單抗
|
1640971-88-5
|
|
Utomilumab
|
烏托魯單抗
|
1417318-27-4
|
|
Telisotuzumab
|
特立妥珠單抗
|
1781223-80-0
|
|
Aprutumab
|
阿普盧妥單抗
|
1634620-63-5
|
|
Elezanumab
|
依來努單抗
|
1791416-49-3
|
|
Lutikizumab
|
魯吉珠單抗
|
1791411-57-8
|
|
Eptinezumab
|
依普奈珠單抗
|
1644539-04-7
|
|
Fremanezumab
|
瑞瑪奈珠單抗
|
1655501-53-3
|
|
Dezamizumab
|
迪扎米珠單抗
|
1662664-56-3
|
|
Suptavumab
|
舒他伏單抗
|
1629615-23-1
|
|
Birtamimab
|
泊特埃單抗
|
1608108-91-3
|
|
Rozanolixizumab
|
洛利昔珠單抗
|
1584645-37-3
|
|
Galcanezumab
|
伽奈珠單抗
|
1578199-75-3
|
|
Erenumab
|
厄瑞努單抗
|
1582205-90-0
|
|
Carotuximab
|
卡羅妥昔單抗
|
1268714-50-6
|
|
Timolumab
|
替莫魯單抗
|
1073538-99-4
|
|
Lanadelumab
|
拉那魯單抗
|
1426055-14-2
|
|
Vonlerolizumab
|
珀伽利珠單抗
|
1638935-72-4
|
|
Duvortuxizumab
|
度妥昔珠單抗
|
1831098-91-9
|
|
SR1664
|
|
1338259-05-4
|
|
JYN42346
|
|
1903742-34-6
|
|
AZD-1940
|
|
881413-29-2
|
|
GI 181771
|
|
305366-98-7
|
|
JQKD-82
|
|
2410512-38-6
|
|
Amivantamab
|
埃萬妥單抗
|
2171511-58-1
|
|
Indusatumab Vedotin
|
|
1514889-12-3
|
|
Plozalizumab
|
洛扎利珠單抗
|
1610761-46-0
|
|
Trevogrumab
|
曲戈盧單抗
|
1429201-24-0
|
|
Inebilizumab
|
英比利珠單抗
|
1299440-37-1
|
|
Navivumab
|
那韋伏單抗
|
1443004-16-7
|
|
Tomaralimab
|
托拉利單抗
|
1449294-76-1
|
|
Losatuxizumab
|
羅妥昔珠單抗
|
1801544-27-3
|
|
Rovalpituzumab
|
洛伐妥珠單抗
|
1613313-01-1
|
|
Rinucumab
|
利努蘇單抗
|
1569263-06-4
|
|
Risankizumab
|
利散吉珠單抗
|
1612838-76-2
|
|
Opicinumab
|
奧匹努單抗
|
1422268-07-2
|
|
Clivatuzumab Tetraxetan
|
泰坦-克利妥珠單抗
|
1462876-11-4
|
|
Ascrinvacumab
|
阿伐蘇單抗
|
1463459-96-2
|
|
Monalizumab
|
莫那利珠單抗
|
1228763-95-8
|
|
Lilotomab
|
利洛托單抗
|
1453362-55-4
|
|
Afasevikumab
|
阿法庫單抗
|
1589503-30-9
|
|
Ifabotuzumab
|
|
1234137-51-9
|
|
Bleselumab
|
布來魯單抗
|
1453067-91-8
|
|
BioE-1197
|
|
1268863-69-9
|
|
INE963
|
|
2640567-43-5
|
|
RY785
|
|
1393748-80-5
|
|
Setrusumab
|
|
1847394-95-9
|
|
Depatuxizumab
|
迪妥昔珠單抗
|
1471999-69-5
|
|
Crizanlizumab
|
立贊利珠單抗
|
1690318-25-2
|
|
Mirvetuximab
|
米妥昔單抗
|
1453084-36-0
|
|
Enoblituzumab
|
依諾妥珠單抗
|
1353485-38-7
|
|
Indusatumab
|
英度妥單抗
|
1497400-26-6
|
|
Ensitrelvir fumarate
|
恩賽特韋富馬酸鹽
|
2757470-18-9
|
|
TH5427
|
|
2253744-56-6
|
|
2,4-Imidazolidinedione, 5-[3-[[4-[(3-methylphenyl)methoxy]phenyl]thio]-2-furanyl]-
|
|
877176-23-3
|
|
Ro60-0175
|
|
169675-08-5
|
|
Obiltoxaximab
|
奧托薩昔單抗
|
1351337-07-9
|
|
SCD1 inhibitor-3
|
|
1282606-48-7
|
|
1-Piperidinamine, N-hydroxy-N-nitroso-
|
|
56329-24-9
|
|
(R)-GSK-3685032
|
|
2170140-50-6
|
|
SUC-ALA-ALA-PRO-PHE-PNA
|
|
107409-54-1
|
|
FTO-IN-3
|
|
2585198-87-2
|
|
GSK251
|
|
2125968-05-8
|